Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer

Acta Oncologica

Volumn 46, Issue 7, 2007, Pages 982-988

  Sørbye, Halfdan ^a   Berglund, Åke ^b   Tveit, Kjell Magne ^c   Øgreid, Dagfinn ^d   Wanderås, Eva Hoff ^e   Wentzel Larsen, Tore ^a   Dahl, Olav ^a   Glimelius, Bengt ^b,f  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d STAVANGER UNIVERSITY HOSPITAL   (Norway)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEALTH STATUS; HUMAN; LIVER SURGERY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; PERFORMANCE; PREDICTOR VARIABLE; PRIORITY JOURNAL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 34848911200     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860701261568     Document Type: Article

References (29)

1. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005;352:476-87.
2. Nygren P, Sørbye H, Østerlund P, Pfeiffer P. Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: An Acta Oncologica expert report. Acta Oncol 2005;44:203-17.
3. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209-14.
4. Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: Current options, current evidence. J Clin Oncol 2005;23:4553-60.
5. Rougier, Lepere C. Second-line treatment of patients with metastatic colorectal cancer. Semin Oncol 2005;32(Suppl 9):S48-S54.
6. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004;22:229-37.
7. Poston GJ, Adam R, Alberts S, Curley S, Figueras J, Haller D, et al. OncoSurge: A strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol 2005;23:7125-34.
8. Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhill SR, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: A North Central Cancer Treatment Group phase II study. J Clin Oncol 2005;23:9243-9.
9. Bismuth H, Adam R, Levi F, Farabos C, Waechter F, Castaing D, et al. Resection of non-resectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996;224:509-22.
10. Sørbye H, Glimelius B, Berglund Å, Fokstuen T, Tveit KM, Brændengen M, et al. Multicentre phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2004;22:31-8.
11. Sørbye H, Dahl O. Nordic 5-fluorouracil/leucovorin bolus schedule combined with oxaliplatin (Nordic FLOX) as first-line treatment of metastatic colorectal cancer. Acta Oncol 2003;42:827-31.
12. Glimelius B, Ristamäki R, Kjaer M, Pfeiffer P, Skovsgaard T, Tveit KM, et al. Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer. Ann Oncol 2002;13:1868-73.
13. Glimelius B, Sørbye H, Balteskard L, Bystrom P, Pfeiffer P, Tveit KM, et al. Randomised phase III multicenter trial comparing irinotecan in combination with either the Nordic bolus 5FU and folinic acid (5FU/FA) schedule (FLIRI) or the bolus/infused de Gramont schedule (FOLFIRI), in patients with metastatic colorectal cancer. ECCO 13-The European Cancer Conference, Paris, France. Abstract 597, 2005.
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. JNCI 2000;92:205-16.
15. Harrell FE. Regression modelling strategies: With applications to linear models logistic regression and survival analysis. New York: Springer-Verlag; 2001.
16. Kohne CH, Cunningham D, Di Costanzo F, Glimelius B, Blijham G, Aranda E, et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: Results of a multivariate analysis of 3825 patients. Ann Oncol 2002;13:308-17.
17. Bensmaine MA, Marty M, de Gramont A, Brienza S, Levi F, Ducreux M, et al. Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU)±folinic acid in a compassionate-use cohort of 481 5-FU resistant advanced colorectal cancer patients. Br J Can 2001;85:509-17.
18. Mitry E, Douillard JY, van Cutsem E, Cunningham D, Magherini E, Mery-Mignard D, et al. Predictive factors of survival in patients with advanced colorectal cancer: An individual data analysis of 602 patients included in irinotecan phase III trials. Ann Oncol 2004;15:1013-7.
19. Cunningham D, Pyrhonen S, James RD, Punt C, Hickish TF, Heikkila R, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-8.
20. Rougier P, Van Cutsem E, Bajetta C, Niederle N, Possinger K, Labianca R, et al. Randomised trial of irinotecan versus fluorouracil by continuos infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407-12.
21. Rothenburg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial. J Clin Oncol 2003;21:2059-69.
22. Ulrich-Pur H, Kornek GV, Fiebiger W, Gedlicka C, Raderer M, Lenauer A, et al. Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy. Ann Oncol 2001;12:1269-72.
23. Stickel F, Jungert B, Brueckl V, Schirner I, Brueckl WM, Mannlein G, et al. Weekly high-dose 5-fluorouracil as 24-h infusion and folinic acid (AIO) plus irinotecan as second- and third-line treatment in patients with colorectal cancer pre-treated with AIO plus oxaliplatin. Anti-Cancer Drugs 2003;14:745-9.
24. Recchia F, Saggio G, Nuzzo A, Lalli A, Di Lullo L, Cesta A, et al. Multicentre phase II study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOX. Br J Can 2004;91:1442-6.
25. Mabro M, Louvet C, Andre T, Carola E, Gilles-Amar V, Artru P, et al. Bimonthly leucovorin, infusional 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer. Am J Clin Oncol 2003;26:254-8.
26. Mabro M, Artru P, Andre T, Flesch M, Maindrault-Goebel F, Landi B, et al. A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients. Br J Cancer 2006;94:1287-92.
27. Blanke CD. Whither irinotecan? J Clin Oncol 2005;23:4811-4.
28. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy. Ann Surg 2004;240:644-58.
29. Delaunoit T, Alberts SR, Sargent DJ, Green E, Goldberg RM, Krook J, et al. Chemotherapy permits resection of metastatic colorectal cancer: Experience from Intergroup N9741. Ann Oncol 2005;16:425-9.